Tanezumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tanezumab" in English language version.

refsWebsite

Global rank English rank

4web.archive.org

1^st place

3doi.org

2^nd place

3nih.gov

4^th place

3clinicaltrials.gov

5,225^th place

4,062^nd place

3fda.gov

447^th place

338^th place

2semanticscholar.org

11^th place

8^th place

1genengnews.com

low place

6,625^th place

1seekingalpha.com

5,344^th place

3,420^th place

1europa.eu

68^th place

117^th place

clinicaltrials.gov (Global: 5,225^th place; English: 4,062^nd place)

Clinical trial number NCT00733902 for "Tanezumab in Osteoarthritis of the Knee" at ClinicalTrials.gov
Clinical trial number NCT00744471 for "Tanezumab in Osteoarthritis Of The Hip" at ClinicalTrials.gov
"Phase II trials involving Tanezumab". ClinicalTrials.gov. U.S. National Library of Medicine.

doi.org (Global: 2^nd place; English: 2^nd place)

Oo WM, Hunter DJ (November 2021). "Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review". BioDrugs. 35 (6): 611–641. doi:10.1007/s40259-021-00504-8. PMID 34807432. S2CID 244509341.
Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A (July 2005). "Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis". Pain. 116 (1–2): 8–16. doi:10.1016/j.pain.2005.03.039. PMID 15927377. S2CID 36145654.
Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR (July 2013). "Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial". Arthritis and Rheumatism. 65 (7): 1795–1803. doi:10.1002/art.37950. PMID 23553790.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Raylumis: Pending EC decision". European Medicines Agency. 17 September 2021. Retrieved 17 September 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov (Global: 447^th place; English: 338^th place)

"Tanezumab Arthritis Advisory Committee Briefing Document" (PDF). US Food and Drug Administration. 8 February 2012. Archived from the original (PDF) on 19 January 2017.
Verburg K. "Monoclonal Antibodies Targeted Against Nerve Growth Factor For the Treatment of Chronic Pain" (PDF). Medicines Development Group, Pfizer Inc. Archived from the original (PDF) on 9 May 2017.
"Transcript for the March 25, 2021 Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee". US Food and Drug administration. 25 March 2021. Archived from the original on July 30, 2021. Retrieved 22 February 2022.

genengnews.com (Global: low place; English: 6,625^th place)

"Trials Halted as Pfizer's Tanezumab Shown to Worsen Osteoarthritis". Genetic Engineering & Biotechnology News. 24 June 2010. Archived from the original on 23 January 2013.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Oo WM, Hunter DJ (November 2021). "Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review". BioDrugs. 35 (6): 611–641. doi:10.1007/s40259-021-00504-8. PMID 34807432. S2CID 244509341.
Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A (July 2005). "Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis". Pain. 116 (1–2): 8–16. doi:10.1016/j.pain.2005.03.039. PMID 15927377. S2CID 36145654.
Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR (July 2013). "Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial". Arthritis and Rheumatism. 65 (7): 1795–1803. doi:10.1002/art.37950. PMID 23553790.

seekingalpha.com (Global: 5,344^th place; English: 3,420^th place)

"Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain". Seeking Alpha. PR Newswire. February 19, 2019.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Oo WM, Hunter DJ (November 2021). "Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review". BioDrugs. 35 (6): 611–641. doi:10.1007/s40259-021-00504-8. PMID 34807432. S2CID 244509341.
Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A (July 2005). "Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis". Pain. 116 (1–2): 8–16. doi:10.1016/j.pain.2005.03.039. PMID 15927377. S2CID 36145654.

web.archive.org (Global: 1^st place; English: 1^st place)

"Trials Halted as Pfizer's Tanezumab Shown to Worsen Osteoarthritis". Genetic Engineering & Biotechnology News. 24 June 2010. Archived from the original on 23 January 2013.
"Tanezumab Arthritis Advisory Committee Briefing Document" (PDF). US Food and Drug Administration. 8 February 2012. Archived from the original (PDF) on 19 January 2017.
Verburg K. "Monoclonal Antibodies Targeted Against Nerve Growth Factor For the Treatment of Chronic Pain" (PDF). Medicines Development Group, Pfizer Inc. Archived from the original (PDF) on 9 May 2017.
"Transcript for the March 25, 2021 Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee". US Food and Drug administration. 25 March 2021. Archived from the original on July 30, 2021. Retrieved 22 February 2022.

Tanezumab (English Wikipedia)

clinicaltrials.gov (Global: 5,225th place; English: 4,062nd place)

doi.org (Global: 2nd place; English: 2nd place)

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

fda.gov (Global: 447th place; English: 338th place)

genengnews.com (Global: low place; English: 6,625th place)

nih.gov (Global: 4th place; English: 4th place)